T cells recognizing truly leukemia-specific antigens like bcr/abl or other leukemia-associated antigens such as proteinase3 and WT1 have been demonstrated by several groups. In chronic myeloid leukemia (CML), DC and leukemic cells share a common progeny, leading to constitutive expression of putative tumor antigens such as bcr/abl in DC.

Aim of our clinical GMP study was the use of autologous DC as a vaccine in patients with chronic phase bcr/abl+ CML, who had not achieved a major cytogenetic response after treatment with imatinib or a-interferon. Primary endpoint of the study were feasibility and toxicity of DC vaccination, secondary endpoints were reduction of bcr/abl+ mononuclear cells in peripheral blood (measured by FISH and quantitative PCR) and induction of an immune response against leukemia-associated antigens. 10 patients were enrolled, 9 patients did receive the vaccine. DC were generated by leukapheresis from peripheral blood monocytes. DC were cultured in RPMI 1640 supplemented with clinical grade FCS in the presence of GM-CSF (100 ng/ml) and IL-4 (1000U/ml). Final maturation was achieved by addition of TNF-a (50 ng/ml) for 3 days. Flowcytometric analysis on day 8/9 of the cell culture showed that DC had a mature phenotype with strong expression of CD80, CD86, CD83 and HLA-DR. In all patients sufficient numbers of functional DC could be generated. By FISH analysis it could be demonstrated that the mean value of bcr/abl-positive cells in the DC cultures was 33% (range: 3–70%). DC were pulsed with KLH for 3–4 hours prior to clinical use. Vaccination was performed by subcutaneous injection in the inguinal region on days 1, 2, 8 and 21 using increasing numbers of DC per injection (1 to 50 x 10e6 cells per injection). 36 vaccinations were performed in nine patients. The follow-up period was three months.

There was no severe toxicity, all vaccinated patients developed a strong DTH reaction, mostly after the third vaccination. In 5/9 patients bcr/abl+ PBMC decreased over the vaccination period, in 2/4 patients quantitative PCR also showed a decrease of bcr/abl in peripheral blood. Only in one of these patients this decrease could clearly be attributed to changes in concomitant therapy during the post-vaccination period. In two patients low frequency T cells recognizing the bcr/abl fusion region were detected by ELISpot or tetramer staining. In all patients PBMC showed an increase in the proliferative response against autologous DC over the post-vaccination period, this increase was partially due to immunization against FCS.

We conclude that vaccination of CML patients after large scale GMP generation of bcr/abl+ DC is feasible and safe. Leukemic DC are able to induce T cell activation. A decrease in tumor cell burden/circulating bcr/abl+ cells in some patients suggests that vaccination with DC might possibly be useful as post remission therapy in CML patients after imatinib.

Author notes

Corresponding author

Sign in via your Institution